Longaeva Partners »

Enliven Therapeutics shares owned by Longaeva Partners

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Longaeva Partners from 13F filings

Historical chart of Longaeva Partners investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Longaeva Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Longaeva Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $4.4M 113k 39.20

More positions owned by Longaeva Partners

Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Boston Scientific Corporation Call Option (BSX)
Bank of America Corporation (BAC)
NVIDIA Corporation Call Option (NVDA)
PNC Financial Services (PNC)
Key (KEY)
Goldman Sachs (GS)
Morgan Stanley Com New (MS)
Minimed Group
Citizens Financial (CFG)
Evercore Class A (EVR)
Mastercard Incorporated Cl A (MA)
Msci (MSCI)
S&p Global (SPGI)
Us Bancorp Com New (USB)

View all positions for Longaeva Partners

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
BlackRock
Polar Capital Holdings
Commodore Capital
Vestal Point Capital
Vanguard Group
Citadel Advisors
Fairmount Funds Management
VR Adviser
Novo A/S
Geode Capital Management
State Street Corporation
Logos Global Management
Pictet Asset Management Holding SA

View all funds holding Enliven Therapeutics